semaglutide euglycemic dka GLP-1 receptor agonists causing ketoacidosis in patients without diabetes: a brief review Euglycemic diabetic ketoacidosis - ScienceDirect

A safer way to think about risk A safer decision framework is not Are these drugs good or bad? A better framework is: Benefit: What health problem am I trying to treat

Folia Microbiol 69:713722 Chung CF, Lin SC, Juang TY, Liu YC (2020) Shaking rate during production affects the activity of Escherichia coli surface-displayed Candida antarctica lipase A

Both Foundayo (Orforglipron) and Wegovy work on the same GLP-1 pathway, but Wegovy is generally more effective, whereas Foundayo may be considered more convenient and is needle-free

In 2021, semaglutide received regulatory clearance for supporting weight loss, and a related formulation became available under the brand WeGovy, also discussed in relation to weight management

Since 2019, there has been a 1,500% spike in poison center reports involving GLP-1 medications like Ozempic, with 1,678 cases already reported in 2025